Precision Dose: How New Methods Are Improving Cancer Therapy
"Dosimetry procedures for organs-at-risk in peptide receptor radionuclide therapy with lutetium-177 are transforming cancer treatment."
Molecular radiotherapy (MRT) is increasingly relying on precise dosimetry to tailor treatments and improve outcomes. Standardizing dosimetry procedures is crucial for maximizing therapeutic benefits and minimizing harm. A key challenge lies in determining the optimal range of absorbed doses that effectively target tumors while safeguarding organs-at-risk (OAR).
Developing standardized dosimetry methods in molecular radiotherapy presents multifaceted challenges, encompassing drug administration, data acquisition, activity quantification, and absorbed dose computation. Each step introduces variables that impact the accuracy and reproducibility of results. Effective implementation requires careful consideration of patient burden, practicality, cost-effectiveness, and the reliability of obtained data.
In the context of lutetium-177 (¹⁷⁷Lu) peptide receptor radionuclide therapy (PRRT), various approaches have been explored to refine dosimetry. These include phantom studies for improved imaging, adjustments to time-point measurements, kinetic and radiobiological modeling, and organ- and voxel-scale dosimetry based on Monte Carlo simulations. This article will discuss how these strategies improve cancer therapy.
From Ancient Treatments to Modern Dosimetry
Cancer has been known to humanity for thousands of years, with historical evidence from ancient Egyptian and Greek civilizations documenting a medical history spanning millennia. The National Cancer Institute's timeline highlights landmark discoveries across the past 250 years, while historical reviews describe early treatment as largely reliant on ineffective radical surgery and cautery. In nuclear medicine therapy, dosimetry has played a vital role since the earliest applications by supporting treatment optimization, safety, and efficacy.
Enhancing Precision in Dosimetry: A Multi-Step Approach
A recent study detailed a dosimetry procedure for organs-at-risk during ¹⁷⁷Lu-DOTATATE therapy, involving 47 patients with neuroendocrine tumors (NETs). The process integrates SPECT/CT imaging with blood sample analysis to enhance accuracy and minimize patient discomfort.
- Drug Administration: Administering lutetium-177 based radiopharmaceuticals.
- Data Acquisition: Serial SPECT/CT images were obtained at 4, 24, and 168 hours post-injection. Blood samples were taken at similar time points, along with additional samples within the first hour to capture early clearance.
- Activity Quantification: PMOD software was used to measure volumes and activity concentrations in kidneys, spleen, liver, red marrow, and the remainder of the body, using volumes of interest (VOIs) on SPECT/CT images.
- Dose Computation: Time-integrated activity coefficients (TIACs) were calculated using bi-exponential fits, and OLINDA/EXM software was used to compute absorbed doses to organs-at-risk.
More Precise Dose Estimation
Recent research is refining how absorbed dose is estimated in targeted radionuclide therapy. A study of [177Lu]Lu-DOTATATE treatment reported a mean patient-cohort bone-marrow absorbed dose of 56.7 mGy/GBq, consistent with previously published reports and toward the upper end of the reported range. Individual dosimetry has also been implemented to help predict tumor dose and normal-organ toxicity, while software such as OLINDA/EXM has been used to calculate absorbed doses for organs at risk in 177Lu-PSMA therapy for metastatic castration-resistant prostate cancer.
Why Precision Remains Difficult
Dosimetry is not free from uncertainty: variations can arise during machine calibration, treatment planning, and patient setup. A review of 26 low-dose radiation studies assessed the quality of their dosimetry systems, showing that measurement quality remains an important consideration in the evidence base. At the same time, radiopharmaceutical therapy is expanding rapidly, making dosimetry critical for optimizing administered activity so tumor-absorbed dose is maximized while normal-organ exposure is limited.
Comparing Tools and Measurements
Different dosimetry approaches address different parts of the dose-estimation problem. National Cancer Institute investigators describe tools that improve dose-estimate accuracy while quantifying and incorporating related uncertainties, and make those tools freely available to radiation dosimetrists and epidemiologists. In radiotherapy quality assurance, gamma analysis compares planned and measured dose distributions within specified tolerances, while single-time-point SPECT methods for radiopharmaceutical therapy remain an alternative to multi-time-point dosimetry, which is described as the gold standard.
Future Directions in Personalized Cancer Treatment
The described dosimetry procedure offers a practical approach for routine clinical implementation, balancing accuracy with patient comfort. Results from this study align with findings from other research centers, reinforcing the reliability and applicability of the method.
Radiobiology and Clinical Judgment
Targeted radionuclide therapy has a long history but has only recently attracted attention as a major contributor to cancer therapy. Expert commentary links radiopharmaceutical therapy with radiobiology, biomarkers, and dosimetry, underscoring the need to interpret dose within a broader biological and clinical framework. For stage III non-small-cell lung cancer, multiple radiotherapy methods are available, and a multidisciplinary tumor board is recommended to determine the best treatment strategy.
Toward Adaptive, AI-Assisted Planning
Future medical dosimetry may incorporate artificial intelligence, adaptive planning, evolving education, brachytherapy, and new research opportunities. Research in radiation oncology continues to develop techniques intended to improve the accuracy and precision of radiotherapy delivery and strengthen the evidence supporting treatment and outcomes. The wider use of patient-specific molecular radiotherapy dosimetry may also influence whether gamma cameras tailored for dosimetry become routine, particularly for large patient cohorts.
Making Precision Work in Practice
Real-world implementation depends on translating dosimetry methods into coordinated clinical workflows. A Dartmouth Cancer Center case study describes building a single dosimetry pool to support four locations using the “OUR Way” method, while also identifying opportunities for standard work and formal organizational steps. Separate case studies report that post-therapy imaging and dosimetry can affect patient management, illustrating how measurement can move from technical assessment into practical care decisions.
By standardizing dosimetry procedures, researchers and clinicians can better understand the relationship between radiation dose and therapeutic outcomes, potentially leading to more individualized and effective treatments. Collaborative efforts to share and refine these techniques will further enhance the precision and safety of molecular radiotherapy.
As dosimetry methods become more refined and accessible, personalized cancer treatment strategies will become a reality, promising improved outcomes and reduced side effects for patients undergoing radionuclide therapy.